- Home
- THCH vs ACET Comparison
THCH vs ACET Comparison
Compare THCH & ACET Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THCH
- ACET
- Stock Information
- Founded
- THCH 2018
- ACET 1947
- Country
- THCH China
- ACET United States
- Employees
- THCH N/A
- ACET N/A
- Industry
- THCH Blank Checks
- ACET Biotechnology: Pharmaceutical Preparations
- Sector
- THCH Finance
- ACET Health Care
- Exchange
- THCH Nasdaq
- ACET Nasdaq
- Market Cap
- THCH 110.9M
- ACET 109.6M
- IPO Year
- THCH N/A
- ACET N/A
- Fundamental
- Price
- THCH $0.66
- ACET $0.95
- Analyst Decision
- THCH
- ACET Strong Buy
- Analyst Count
- THCH 0
- ACET 4
- Target Price
- THCH N/A
- ACET $5.67
- AVG Volume (30 Days)
- THCH 123.0K
- ACET 466.3K
- Earning Date
- THCH 11-12-2024
- ACET 11-06-2024
- Dividend Yield
- THCH N/A
- ACET N/A
- EPS Growth
- THCH N/A
- ACET N/A
- EPS
- THCH N/A
- ACET N/A
- Revenue
- THCH $207,029,179.00
- ACET N/A
- Revenue This Year
- THCH N/A
- ACET N/A
- Revenue Next Year
- THCH N/A
- ACET N/A
- P/E Ratio
- THCH N/A
- ACET N/A
- Revenue Growth
- THCH N/A
- ACET N/A
- 52 Week Low
- THCH $0.57
- ACET $0.93
- 52 Week High
- THCH $2.30
- ACET $3.77
- Technical
- Relative Strength Index (RSI)
- THCH 41.45
- ACET 20.89
- Support Level
- THCH $0.65
- ACET $1.20
- Resistance Level
- THCH $0.78
- ACET $1.40
- Average True Range (ATR)
- THCH 0.07
- ACET 0.10
- MACD
- THCH -0.00
- ACET -0.04
- Stochastic Oscillator
- THCH 20.00
- ACET 3.25
About THCH TH International Limited Ordinary shares
TH International Ltd is the parent company of the franchise of Tim Hortons coffee shops and has the rights to operate Tim Hortons coffee shops in mainland China, Hong Kong, and Macau. Through the Tim Hortons brand, the firm offers freshly brewed coffee, tea, and other beverages, bakery & sides, and sandwiches. It is also the operator and developer of Popeyes brand in Mainland China. The firm has two reportable segments; Tim Hortons which generates key revenue, and Popeyes. The company's revenue is derived from its operations in the PRC.
About ACET Adicet Bio Inc.
Adicet Bio Inc is a clinical-stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for cancer and other diseases. Its lead product candidate, ADI-001, a first-in-class allogeneic gamma delta T cell therapy expressing a CAR targeting CD20, is being developed for the potential treatment of autoimmune diseases and relapsed or refractory aggressive B cell non-Hodgkin's lymphoma. Their pipeline also includes its lead preclinical candidate, ADI-270, an armored gamma delta CAR T cell product candidate targeting renal cell carcinoma, with potential for other CD70+ solid tumor and hematological malignancies indications.